ArticleBMC musculoskeletal disorders2010
The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis.
Article in BMC musculoskeletal disorders, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- The first involved joints and associated factors in patients with rheumatoid arthritis.Archives of rheumatology · 2024Article
- Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance.Annals of the rheumatic diseases · 2023Article
- Sustained DMARD-free remission in rheumatoid arthritis - about concepts and moving towards practice.Joint bone spine · 2022Review
- Rheumatoid Arthritis Co-relation with Anti-CCP Antibodies with special reference to its Prevalence in Asymptomatic First-Degree Relatives.Mediterranean journal of rheumatology · 2022Article
- The current status of anti-citrullinated protein antibodies and citrullinated protein-reactive B cells in the pathogenesis of rheumatoid arthritis.Molecular biology reports · 2022Review
- Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis.Nature reviews. Rheumatology · 2021Review
- Article
- The Clinical Value of Autoantibodies in Rheumatoid Arthritis.Frontiers in medicine · 2018Review
- Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.Rheumatology international · 2016Review
- CCR6(+) Th cell populations distinguish ACPA positive from ACPA negative rheumatoid arthritis.Arthritis research & therapy · 2015Article
- Circulating anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease.Rheumatology international · 2014Article
- Elevated serum IgG4 defines specific clinical phenotype of rheumatoid arthritis.Mediators of inflammation · 2014Article
- Anti-cyclic citrullinated peptide antibody is a good indicator for the diagnosis of rheumatoid arthritis.Pakistan journal of medical sciences · 2013Article
- Article
- Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease?Clinical rheumatology · 2012Article
- Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: association with disease parameters and quality of life.Clinical rheumatology · 2012Article
- The influence of ACPA status and characteristics on the course of RA.Nature reviews. Rheumatology · 2012Review
- Anti-CCP antibodies: the past, the present and the future.Nature reviews. Rheumatology · 2011Review
- Relationship between time-integrated disease activity estimated by DAS28-CRP and radiographic progression of anatomical damage in patients with early rheumatoid arthritis.BMC musculoskeletal disorders · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAnti-cyclic citrullinated peptide (anti-CCP) antibodies are highly specific for RA, but are not detectable in all RA patients. The aim of this study was to establish whether the clinical phenotypes of anti-CCP positive and negative disease are distinct at the earliest clinically apparent phase of disease.
methodsPatients were recruited from the Birmingham early inflammatory arthritis clinic. Participants were included in the current study if they presented within 3 months of symptom onset and fulfilled 1987 ACR criteria for RA at some point during an 18 month follow-up. Data were collected on demographic variables, joint symptoms and tender (n = 68) and swollen (n = 66) joint counts. CRP, ESR, rheumatoid factor and anti-CCP2 status were measured.
results92 patients were included (48 anti-CCP positive). The anti-CCP positive and negative groups were comparable in terms of demographic variables, inflammatory markers, joint counts and 1987 ACR classification criteria, except that more anti-CCP positive patients were rheumatoid factor positive (83.3% vs. 11.4%, p < 0.01). There was no significant difference in the pattern of joint involvement, except for an increased prevalence of knee joint swelling in anti-CCP positive patients (42.9% vs. 22.2%, p = 0.03).
conclusionsPatients with and without anti-CCP antibodies present in a similar way, even within three months of clinically apparent disease that eventually develops into RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.